On Sunday, November 2, 2025, NMD Pharma will lace up their running shoes and take on the TCS New York City Marathon—not just for the challenge, but for the 3 million people worldwide living with Charcot-Marie-Tooth disease (CMT).
As an HNF TRIAD partner, NMD Pharma is leading the way with innovative science, including NMD670, a promising therapy currently in Phase II clinical trials for CMT1 and CMT2. But today, their commitment goes beyond the lab.
They’re running for:
- Critical research funding to accelerate breakthroughs
- Ongoing clinical trials bringing us closer to treatment
- The strength and resilience of the CMT community
- Hope for a future with real therapies
Every step counts—and so does your support.
Donate or cheer on Team NMD Pharma
Together, we can turn Passion for Movement into lasting impact for families living with CMT. Whether you donate, share their page, or send encouragement, your support fuels both their strides and their science.
Learn more about NMD Pharma’s CMT clinical trial in this year’s HNF CMT Summit, keynote from Thomas Holmes.
Let’s go the distance—for a world without CMT.
0 Comments